KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBITDA: 2017-2025

Historic EBITDA for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $70.3 million.

  • Amneal Pharmaceuticals' EBITDA fell 20.79% to $70.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $357.9 million, marking a year-over-year increase of 90.63%. This contributed to the annual value of $249.3 million for FY2024, which is 21.99% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' EBITDA stood at $70.3 million, which was down 36.84% from $111.4 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' EBITDA's 5-year high stood at $111.4 million during Q2 2025, with a 5-year trough of -$198.6 million in Q2 2022.
  • Moreover, its 3-year median value for EBITDA was $75.8 million (2024), whereas its average is $66.9 million.
  • In the last 5 years, Amneal Pharmaceuticals' EBITDA soared by 1,071.05% in 2021 and then slumped by 395.92% in 2022.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' EBITDA stood at $11.2 million in 2021, then soared by 222.43% to $36.0 million in 2022, then crashed by 60.61% to $14.2 million in 2023, then soared by 434.02% to $75.8 million in 2024, then declined by 20.79% to $70.3 million in 2025.
  • Its EBITDA was $70.3 million in Q3 2025, compared to $111.4 million in Q2 2025 and $100.3 million in Q1 2025.